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Case presentation
A 35-year-old white woman came to the hospital complaining
of severe weakness of several days duration. She had a 20-year
history of anorexia nervosa, recently eating only cheese,
unsalted crackers, chicken soup, and dilute lemonjuice. For the
past several years, she had taken 2 Ex-lax tablets per day and
she excreted one soft bowel movement daily. She noted urinary
frequency with polyuria, nocturia, and polydipsia; she drank
approximately 12 glasses of fluid per day. She was in her usual
state of health until one week prior to admission when she fell
twice on ice. Over the week, she had moderate amounts of
watery diarrhea, walked more slowly, and had difficulty climb-
ing stairs. On the morning of admission, she collapsed on the
floor, could not get up unaided, and was unable to dress herself.
The medical history was positive only for amenorrhea for the
past 12 years. She had never been hospitalized or sought
psychiatric evaluation and had not seen a physician for more
than 4 years.
Physical examination revealed a blood pressure of 100/60mm
Hg; pulse, 80/mm; respiratory rate, 22/mm; temperature, 98.6°
F; and weight, 37,7 kg. There were no orthostatic changes and
she appeared euvolemic. The only abnormal finding was prox-
imal muscle weakness of both arms and legs greater than
expected for her poor nutritional status.
Laboratory studies showed a hematocrit of 40%; white blood
cell count, 11,400 mm3 with a normal differential; BUN, 21
mg/dl; creatinine, 0.7 mg!dl; and glucose, 88 mg/dl. The sodium
was 141; potassium, 1.6; and chloride, 100 mEq/liter. The
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bicarbonate was 29 mmol/liter; calcium, 9.4 mg/dl; phosphate,
2,4 mg/dl; magnesium, 2.2 mEq/liter; and creatine phosphoki-
nase (CPK), 798 U. Urinalysis had a specific gravity of 1.001;
pH, 7.0; and negative protein and sediment. The electrocar-
diogram showed flattened T waves and prominent U waves.
Within the first few hours of admission, urinary electrolytes on
a random specimen had a sodium concentration of 33 mEq/liter;
potassium, 7 mEq/liter; chloride, 63 mEq/Iiter; and bicarbonate,
0 mEq/Iiter. An arterial blood gas had a P02 of 78 mm Hg;
PCO2, 34 mm Hg; and pH, 7.46.
Figure 1 shows the initial potassium replacement and serum
potassium levels. After she received 20 mEq of intravenous and
280 mEq of oral potassium chloride over 6 hours, the serum
potassium had risen only to 2.1 mEq/liter. However, when an
additional 60 mEq of intravenous and 180 mEq of oral potas-
sium chloride was given over the next 5 hours, she complained
of tingling sensations and muscle twitching. Chvostek's and
Trousseau's signs were positive. She was treated with 2 g
calcium chloride and I g magnesium chloride intravenously.
Repeated blood studies and arterial blood gas levels were
substantially unchanged, except for the serum potassium,
which was now 8.3 mEq/liter, and the CPK, which was 2400
with 7% MB isoenzyme. An electrocardiogram showed peaked
T waves over the precordium. After the hyperkalemia was
discovered, 50 mEq sodium bicarbonate, 10 units crystalline
zinc insulin, and 50 ml 50% dextrose were given intravenously.
By 4 hours later, the serum potassium had fallen to 4.0
mEq/liter; symptoms and electrocardiographic abnormalities
had resolved. The CPK returned to normal over the next
several days, and all chemistries remained normal.
Discussion
Da. ROBERT S. BROWN (Clinical Chief, Renal Unit, and
Associate Physician, Beth Israel Hospital, and Associate Pro-
frssor of Medicine, Harvard Medical School, Boston, Massa-
chusetts): This unusual 35—year-old woman presented with
severe hypokalemia caused by the concurrence of a low potas-
sium intake due to anorexia nervosa and an increased fecal
potassium loss due to chronic laxative abuse. Urinary electro-
lyte measurements confirmed that renal potassium conservation
was normal. She exhibited many of the findings seen with
hypokalemia, including the polyuria and polydipsia associated
with defective renal concentrating ability, muscle weakness,
rhabdomyolysis, and electrocardiographic abnormalities. The
house staff gave vigorous potassium replacement, and within 12
hours she developed tetany and life-threatening hyperkalemia.
The experience with this patient poses several questions for us.
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Table 1. Sodium, potassium, and chloride concentrations in
intracellular fluid (ICF) and extracellular fluid (ECF) with the
calculated diffusion potential of each ion
ICF
ECF
E0
Sodium
15 mEq/liter
150 mEq/literb
+62 mV
Potassium
150 mEq/liter
4 mEq/liter
—97 mV
Chloride
3 mEq/liter
115 mEq/literb
—97 mV
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Fig. 1. The patient's serum potassium concentration over the first 28
hours of hospitalization. The doses and times (arrows) of potassium
chloride administered, development of symptoms, and other therapies
are shown (see text).
First, why did the first 300 mEq of potassium chloride cause
only a minimal rise in the serum potassium, from 1.6 to 2.1
mEq/liter? Second, why did an additional load of only 240 mEq
cause her serum potassium to rise to 8.3 mEq/liter? Third, why
did she develop the symptoms of tingling sensations, muscle
twitching, and tetany? I will defer these questions to review
extrarenal potassium physiology and then attempt to answer
them along the way.
Potassium distribution andcellular uptake
The potassium intake in a typical diet ranges from about 60 to
100 mEq/day. Less than 10% of this amount is excreted in the
stool and, assuming sweat losses are small, most of the potas-
sium is excreted in the urine. The kidney, in fact, serves as the
regulatory organ for total body potassium balance over time.
The extracellular fluid contains only 50 to 65 mEq, or less than
2%, of the total body exchangeable potassium stores. It there-
fore is not uncommon for many animals and humans to eat as
much potassium in a single meal as that contained in the entire
extracellular fluid. A potassium load is quickly absorbed from
the gastrointestinal tract but only slowly excreted by the kidney
(often less than one-half of such a potassium load is excreted in
4 to 6 hours), so the protection against hyperkalemia rests on
the distribution of potassium between the intracellular and
extracellular fluid compartments. Most of the approximately
3500 mEq of total exchangeable potassium in the body is within
muscle cells, with lesser amounts in the liver and red blood
cells.
To explain the high potassium concentration within cells, the
membrane theory assumes first, that there are differential ion
permeabilities through the cell membrane that can generate
electrical potentials, and second, that the sodium pump actively
maintains ion gradients and an electrical potential difference
across the cell membrane. Using average values for the con-
centrations of sodium, potassium, and chloride inside muscle
cells and in the extracellular fluid, the Nernst equation can be
a From Ref. 1.
b Corrected for Donnan factors.
used to calculate the equilibrium potential for each ion (Table
1). As noted in Table 1, the calculated diffusion potentials of
—97 mV for potassium and chloride are quite close to the actual
measured value of about —90 mY for skeletal muscle cells [1].
Therefore, the high intracellular potassium and low intracellular
chloride levels are to be expected by diffusion of these ions
toward their equilibrium concentrations, which are dictated by
the negative electrical potential inside the cell. The fact that the
low intracellular and high extracellular sodium concentrations
yield a calculated equilibrium potential (Table 1) far from the
measured potential is consistent with active sodium transport
against an electrochemical gradient. The electrogenic sodium
pump responsible for sodium transport is sodium-potassium
ATPase bound in the cell membrane. This pump extrudes 3
sodium ions from the cell in exchange for 2 potassium ions.
Therefore, cellular potassium concentration depends mainly on
the activity of sodium-potassium ATPase and on regulation of
the cell membrane permeabilities to sodium and potassium ion.
Together these two factors determine both the electronegative
potential of the cell—so crucial to the function of excitable
tissues such as nerves, heart, and skeletal muscle—and the
uptake of potassium into the cell, an important determinant of
cell volume and osmolality.
Figure 2 shows an action potential of skeletal muscle with a
normal resting potential of —90 mV. In hypokalemia, the cell is
hyperpolarized, with a potassium concentration in the extracel-
lular fluid that has decreased relatively more than that in the
intracellular fluid. The increased electronegativity results in a
larger gap between the resting potential and the threshold
potential at which an action potential is propagated; this gap
presumably accounts for the muscle weakness and eventual
flaccid paralysis that occur with severe hypokalemia. The
reverse situation occurs in hyperkalemia, in which the extra-
cellular potassium concentration has increased relatively more
than that in the cell, with a depolarized resting potential that is
closer to the threshold potential. It seems likely that this
phenomenon also occurs during the rapid replacement of po-
tassium in extremely hypokalemic patients. In this situation,
the rise of extracellular potassium is faster than that in the
potassium-depleted cells and may be associated with a narrow
gap between the resting and threshold potentials analogous to
that of patients with hyperkalemia. The approximation of the
resting potential to the threshold potential, in a manner similar
to that in patients with hypocalcemia (which causes the thresh-
old potential to approach the resting potential), accounts for the
tetany and the positive Chvostek's and Trousseau's signs that
are well described in patients receiving potassium replacement
2]. It is not uncommon for these findings to be transiently
misdiagnosed as indicative of hypocalcemia or hypomagnese-
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Fig. 2. The electrical action potential of skeletal muscle and effect of
potassium balance. The solid horizontal line delineates the normal
threshold potential of depolarization required to propagate an action
potential; the broken line shows the resting potential when potassium
balance is normal. In the potassium-depleted state, the resting potential
is more negative (relatively hyperpolarized), whereas in hyperkalemia,
the resting potential is less negative (relatively depolarized).
mia. That is in fact what occurred in this patient before the
hyperkalemia was recognized.
Determinants of extrarenal
potassium metabolism
When potassium loads that have the potential of doubling or
tripling the extracellular potassium content are ingested, the
avoidance of potassium intoxication depends on extrarenal as
well as renal mechanisms [3]. It has been recognized for many
years that adaptation to potassium loads that would take many
hours to excrete is accomplished by the rapid distribution of
potassium out of the extracellular fluid by cellular uptake.
Alexander and Levinsky gave potassium loads to rats that had
been adapted to a high-potassium diet and that had undergone
bilateral nephrectomy; the plasma potassium concentration
increased much less in these animals than in rats that previously
had been eating a normal potassium diet [4]. Recent evidence
has helped to delineate several mechanisms that modulate
cellular potassium uptake and that might participate in the
adaptive process of extrarenal tolerance to potassium loads. At
least four factors, namely acid-base status, insulin, mineralo-
corticoids, and adrenergic activity, affect the relative distribu-
tion of total body potassium between the intracellular and
extracellular fluids.
Effect of acid-base balance. The ability of acid-base balance
to modulate potassium concentration is well recognized. Aci-
dosis increases the plasma potassium by inducing a shift of
potassium from the intracellular to the extracellular fluid, in
addition to decreasing distal tubular potassium secretion by the
kidney. Alkalosis decreases the plasma potassium by the oppo-
Table 2. Factors modifying the extrarenal effect of acid-base changes
on the plasma potassium
Modulating Factor
Greater
—K7pH
Less
—K/pH
1. Direction of pH change Acidosis Alkalosis
2. Origin of disorder
3. Determinant of plasma
Metabolic
Bicarbonate
Respiratory
PCO2
acidity changed
4. Nature of anion Mineral acid Organic acid
5. Duration of acidosis Hours Minutes
site extrarenal and renal actions. It was a common rule of
thumb that the potassium level would rise approximately 0.5
mEq/liter for each 0.1 fall in blood pH in acidosis [5]. However,
as outlined by Adrogué and Madias and by Perez and col-
leagues, the relationship between pH and potassium changes is
now known to be more complex and less predictable, with
several other factors modulating the response of the plasma
potassium to a given change in pH [6, 71 (Table 2). Acidosis
usually causes a rise in the potassium level that is greater than
the comparable fall in potassium that occurs with alkalosis [6].
Furthermore, metabolic disorders affect the plasma potassium
considerably more than do respiratory ones [6, 8]. Bicarbonate
may play a special role, because a fall in the plasma bicarbonate
produces a significant rise in the plasma potassium, even if a
decrease in the PCO2 keeps the pH relatively constant [9]. The
opposite effect is useful clinically: bicarbonate administration
lowers potassium levels in patients with hyperkalemia even if
the pH is unaffected [10].
Mineral acids produce a larger rise in the plasma potassium
concentration than do organic acids [6, l1—15], presumably
because nonionized organic acids can enter the cell without
causing a reciprocal movement of potassium or sodium out-
wards (as when a cationic proton enters a cell without chloride).
Moreover, when an acid load is given, the pH changes most
initially, but the rise in potassium lags until later [7, 16, 17],
when the hydrogen ion has entered the cells, causing potassium
to exit.
Effect of insulin. Insulin infusions decrease the plasma potas-
sium by enhancing cellular uptake without producing an incre-
ment in renal potassium excretion [3, 18—21]. When potassium
loads are large enough to raise the plasma concentration by at
least I mEq/liter, insulin secretion is stimulated in dogs [19—22]
and in humans [23], thus increasing cellular potassium uptake to
correct hyperkalemia. But with more modest potassium loads
that don't elevate the plasma insulin, the reduction of basal
insulin by somatostatin infusion produces an increased plasma
potassium without decreasing the amount of potassium ex-
creted in the urine [24]. Cellular uptake of potassium can be
restored to normal by restoration of basal insulin levels [24];
thus the basal level of insulin appears to be essential to
potassium homeostasis. Cellular uptake of potassium, when
stimulated by insulin, is initially predominant in splanchnic
tissues, mainly the liver, and subsequently in peripheral tissues,
mainly muscle [25]. In both tissues, potassium uptake is inde-
pendent of insulin-stimulated glucose uptake [18, 25, 26]. This
point is important to remember when using glucose and insulin
in the treatment of hyperkalemia. Glucose should not be given
alone, because if insulin secretion fails, as in a patient with
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unrecognized diabetes, the resultant hyperglycemia and hy-
perosmolality will cause an extracellular shift of water and
potassium and will exacerbate the hyperkalemia [18, 27—29].
Insulin's ability to augment potassium uptake in cell mem-
branes appears to be the consequence of stimulation of the
activity of sodium-potassium ATPase and hyperpolarization of
the cell by a mechanism independent of cyclic AMP [30]. An
additional insulin effect to stimulate sodium-hydrogen exchange
across the cell membrane [31] may also augment potassium
influx secondarily due to the decreased intracellular hydrogen
ion.
Effect of mineralocorticoids, Although mineralocorticoids
have a potent kaliuretic action, the magnitude of their role in
extrarenal potassium metabolism is less well defined. It is well
known that potassium loading and hyperkalemia stimulate
aldosterone secretion by the adrenal zona glomerulosa [32, 331.
When a potassium load was given to anephric rats that had been
adapted to a high-potassium diet, the augmented uptake of
potassium by extrarenal tissues could be abolished by prior
adrenalectomy and could be reproduced without a high-potas-
sium diet by the administration of exogenous mineralocorti-
coids [4]. However, to obtain this effect, the mineralocorticoid
had to be given prior to bilateral nephrectomy, and the dose
used was many times that needed for physiologic replacement
[4]. Aldosterone replacement in doses close to physiologic
levels restored potassium tolerance toward normal in glucocor-
ticoid-replaced, adrenalectomized rats receiving a potassium
load after bilateral nephrectomy [34]. Aldosterone replacement
also caused redistribution of potassium from the extracellular to
the intracellular compartment, and reduced total exchangeable
potassium in adrenalectomized dogs [35]. Mineralocorticoid
administration corrects hyperkalemia in patients with hyporeni-
nemic hypoaldosteronism without producing a detectable in-
crease in renal or fecal potassium excretion [361 and in anuric
dialysis patients [371. The tissue site of this extrarenal effect of
mineralocorticoids remains unclear; unfortunately, studies of
the role of aldosterone in potassium transport by muscle both in
vivo and in vitro have yielded conflicting results [18]. It is clear,
however, that mineralocorticoids have an important effect on
the colon: specifically, they increase potassium and decrease
sodium content in the feces [38, 39]. This effect on potassium
and sodium transport appears to be facilitated by an increase in
potential difference across the colonic epithelium and by an
increase in sodium-potassium ATPase activity [40, 41]. Gluco-
corticoids have effects on the colon similar to those of miner-
alocorticoids [38, 411, but these agents do not correct the defect
in extrarenal potassium disposal caused by adrenalectomy, as
do mineralocorticoids [34]. The mineralocorticoid action is
initiated by binding to high-affinity cytosolic receptors for
aldosterone, so-called type-I receptors, in contrast to the type-
II receptors for the glucocorticoid hormones [42]; type-I recep-
tors have been found in colon [43], hippocampus [44], mam-
mary gland [45], and mononuclear leukocytes [46], in addition
to the kidney [471. Mineralocorticoids also increase potassium
and decrease sodium concentrations in saliva [48, 49] and sweat
[501. In the absence of excessive sweating or diarrhea, how-
ever, the total amount of potassium excreted via these routes
usually is not large enough to play an important role in overall
potassium homeostasis.
Effect of adrenergic activity. Adrenergic activity does play an
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Fig. 3. Effecl of propranolol on the increment in serum potassium
induced by an intravenous potassium load. Changes in serum potas-
sium with potassium loading are denoted by solid circles in the absence
of propranolol and by open circles in the presence of propranolol.
Values plotted indicate mean SEM in 9 subjects. The probability of the
difference between treatments was <0.001 by repeated measure analy-
sis. (Reproduced, by permission of the New England Journal of
Medicine [302:431, 1980].)
important role in potassium distribution. When Silva and
Spokes induced chemical sympathectomy by injection of
6—hydroxydopamine in nephrectomized and adrenalectomized
rats, the cellular uptake of a potassium load was significantly
impaired and caused a greater degree of hyperkalemia [511. This
impairment of potassium tolerance was additive to the defect
caused by streptozotocin-induced insulin deficiency and was
corrected by epinephrine infusion [51]. We have extended these
observations to humans. When healthy subjects were infused
with a potassium load (Fig. 3), the simultaneous administration
of propranolol significantly increased the serum potassium level
and prolonged its elevation without changing urinary potassium
excretion [52]. Moreover, when epinephrine was infused with
the potassium load, the rise in serum potassium was markedly
blunted (Fig. 4), whereas urinary potassium excretion de-
creased [521. Changes in plasma aldosterone or insulin did not
account for these findings; thus, it would appear that beta-
adrenergic stimulation increases, and beta-blockade impairs,
extrarenal disposal of a potassium load. Similar findings have
been described by other investigators in animals [53—59] and in
humans [60, 611.
The increased cellular uptake promoted by epinephrine ap-
pears to be a beta2-specific effect, because it is duplicated by
beta2 agonists but not by beta1 agonists [53, 55, 62, 63] and is
blocked by beta2-selective or nonselective beta antagonists [51,
55, 61, 63—65] but not by beta1-selective antagonists [55, 631 or
alpha antagonists [51, 53, 55, 59]. In contrast to the beta-
adrenergic effect of increasing potassium tolerance via cellular
uptake, aipha-adrenergic stimulation has the opposite effect.
When the alpha-agonist phenylephrine was infused with a
potassium load in healthy human subjects (Fig. 5), the rise in
serum potassium was significantly augmented and prolonged,
despite no change in urinary potassium excretion [66]. Further-
more, the addition of the alpha-antagonist phentolamine
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Fig. 4. Effect of epinephrine on the increment in serum potassium
induced by an intravenous potassium loud. Changes in serum potas-
sium with potassium loading are denoted by open circles in the absence
of epinephriae and by open triangles in the presence of epinephrine.
Values plotted denote mean 5EM in 5 subjects. The overall probability
of the difference between treatments was <0.01 by repeated measure
analysis. (Reproduced, by permission of the New England Journal of
Medicine [302:431, 1980].)
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Fig. 5. Effrct of simultaneous phenylephrine and phentola,nine on the
increment in serum potassium (K) induced by an intravenous potas-
sium chloride (KCI) load. Subjects received phenylephrine in the dose
that produced the highest elevation of the serum potassium level in a
previous study. Values are mean levels (± 5EM) in 7 subjects. The
overall probability of the difference between phenylcphrine and block-
ade with phentolamine was 0.005 by variance analysis. As compared
with control studies, phentolamine blockade lowered potassium levels
overall (P < 0.05 by variance analysis). (Reproduced by permission of
the New England Journal of Medicine [311:145, 1984].)
blocked the rise in potassium produced by phenylephrine (Fig.
5)1661. These findings are consistent with results from studies
of phenylephrine administration in dogs [531 and with the early,
brief hyperkalemie effect of epinephrine, which can be blocked
hy the alpha antagonist phenoxybenzamine [53, 55, 59]. These
observations have been extended to exercise-induced hyperka-
lemia, in which beta blockade with propranolol augments and
prolongs the potassium rise during muscular exercise [67—691,
and in which alpha blockade with phentolamine diminishes the
rise in potassium and lowers the potassium level during recov-
ery [69]. Thus it seems likely that alpha-adrenergic stimulation
impairs, and beta-adrenergic stimulation improves, the extrare-
nal disposal of acute potassium loads.
The cellular mechanism by which beta-adrenergie stimulation
influences muscle cell uptake of potassium depends on specific
binding to beta receptors and subsequent stimulation of adenyl-
ate cyclase. Adenylate cyelase in turn enhances cyclic AMP-
mediated activation of sodium-potassium ATPase, resulting in
sodium etilux and potassium influx [70—73]. The mediation of
catecholamine action via cyclic AMP, in contrast to the action
of insulin (which is independent of cyclic AMP), is consistent
with the additive effects of insulin and epinephrine on potas-
sium transport [30, 72].
Regulation of plasma potassium
Our current knowledge of the major factors controlling
potassium homeostasis is summarized in Figure 6. When
hyperkalemia occurs, as with increased potassium intake, re-
duced excretion, cell lysis, vigorous exercise, or movement of
potassium out of cells, aldosterone is released. Aldosterone
predominantly increases renal potassium excretion, but it also
increases fecal potassium excretion and probably affects cellu-
lar potassium uptake as well. With large potassium loads,
increased insulin secretion augments cellular potassium uptake.
Even with smaller potassium loads, the basal insulin level is
essential to facilitate cellular potassium uptake; thus one finds
frequent impaired potassium tolerance and hyperkalemia in
insulinopenic diabetic patients. Although the plasma epineph-
rine level does not rise with potassium loading [61], beta-
adrenergic activity plays an important role in regulating cellular
potassium uptake. Plasma catecholamine levels are relatively
poor indicators of sympathetic nervous system activity, but
norepinephrine turnover and urinary catecholamine excretion,
which offer better estimates of adrenergic activity, are de-
pressed by fasting and increased by feeding [74]. It seems likely
that when potassium is ingested as part of a meal, the resulting
increased beta-adrenergic activity together with insulin aug-
ment cellular potassium uptake and restore the plasma potas-
sium level to normal. A similar beta-adrenergic effect appears to
reverse the hyperkalemia of exercise by increasing cellular
potassium uptake, thus counteracting the potassium release
that occurs in contracting muscles [67—69]. Conversely, in
hypokalemic states due to inadequate intake, to increased renal
or extrarenal potassium losses, or to increased cellular uptake
of potassium, aldosterone secretion is inhibited. This inhibition
decreases renal and colonic potassium excretion, and possibly
decreases cellular uptake of potassium as well (Fig. 6).
Hypokalemia inhibits insulin secretion [75, 76] and further
decreases cellular potassium uptake to help restore the plasma
potassium level toward normal. Although no data document
augmented alpha-adrenergic activity in hypokalemia, in potas-
sium-depleted rats alpha receptors in skeletal muscle decrease
sodium pump activity and thereby diminish muscle uptake of
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Fig. 6. Schematic diagram of potassium homeostasis. The major mechanisms that restore a depressed or elevated plasma potassium toward
normal and their primary mode of actioo are depicted. The question marks denote uncertainty about the effect of aldosterone on cellular potassium
uptake.
potassium [77, 781. This effect is blocked by phentolamine and
by other alpha-sympatholytic neural ablations [781. It thus
seems likely that alpha-adrenergic activity plays a role in
potassium homeostasis by decreasing cellular potassium up-
take, thus defending the plasma potassium level in chronic
potassium depletion and also in the postexercise state, in which
beta-adrenergic-mediated hypokalemia might occur [691.
Potassium homeostasis in the patient presented
In the patient presented today, why did the serum potassium
increase so little with the first 300 mEq of potassium adminis-
tered, and so much with the last 240 mEq? It is important to
recognize that the relationship of the serum potassium to the
total body potassium is not a linear one. The potassium deficits
must be quite large, over 200 mEq, before substantial
hypokalemia develops (Fig. 7) [791. Therefore, the serum po-
tassium level rises only slowly, despite administration of large
quantities of potassium in severely depleted patients, until the
total body potassium approaches normal. Thereafter the rise of
the serum potassium with additional increments in total body
potassium is much steeper (Fig. 7). It is reasonable to assume
that the first 300 mEq of potassium this patient received (Fig. 1)
resulted in the shallow rise of the serum potassium (shown at
the left side of the curve in Figure 7), as expected in a severely
depleted patient. Moreover, because this patient received most
of the potassium load orally, we can't assume that her intestinal
absorption was as rapid as normal, as severe potassium defi-
ciency decreases gastrointestinal motility 180]. If gastric emp-
tying was delayed because of the effect of hypokalemia on
gastric smooth muscle, it is possible that only a portion of the
potassium administered had been absorbed at the time that her
serum potassium had risen to only 2.1 mEq/liter. The later
influx of a larger proportion of the potassium load (when the
relationship of serum potassium to total body potassium was on
the steep portion of the curve in Figure 7) probably contributed
to the marked rise in her serum potassium to 8.3 mEq/liter.
Some of the mechanisms controlling potassium homeostasis
Fig. 7. Approximate relationship between changes ia lotal body potas-
sium aad the serum concentratioa of potassium in an adult. The graph
depicts a rough gauge of the degree of negative or positive potassium
balance with hypokalemia or hyperkalemia in a 70 kg person. The
shaded area shows that acidosis raises, and alkalosis lowers, the serum
potassium concentration. (Rcproduced, with permission, from Ref. 79.)
that I have described also could explain this phenomenon. The
acute administration of 540 mEq of potassium to a 38 kg person
could possibly cause a transient increase of serum potassium of
as much as 14 mEq/liter, calculated on an apparent volume of
distribution of about 1 liter/kg body weight [811, if the unwar-
ranted assumption is made that all the potassium is absorbed
rapidly from the intestine and none is excreted. Because such a
large dose of potassium was administered to this small woman,
it is apparent that avoidance of transient hyperkalemia de-
pended on adaptive mechanisms that would increase potassium
excretion, and more importantly, on the cellular uptake of
potassium. Her potassium-depleted diet, initial hypokalemia,
and urinary electrolytes showing adequate sodium and chloride
levels but low potassium excretion all indicate that she was
conserving potassium, and this clinical picture is consistent
[Hvpokalemia
Aldosterone Insulin Alpha-adreni1
decrease decreasej activity j
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Table 3. Extrarenal causes of hyperkalemia
Redistribution of potassium from intracellular to extracellular fluid
Acidosis
Insulin deficiency
Beta-adrenergic blockers (beta2 or nonselective)
Aipha-adrenergic agonists
Vigorous exercise
Tissue necrosis
Chemotherapy cell lysis
Digitalis intoxication
Succinylcholine
Arginine infusion
Hyperkalemic periodic paralysis
Redistribution into the serum after phlebotomy (pseudohyperkalemia)
Hemolysis
Platelet release (thrombocytosis)
White blood cell release (leukemia)
with low aldosterone levels. Because the renal and extrarenal
mechanisms take 3 to 4 days to maximally augment potassium
excretion and cellular uptake when potassium intake is in-
creased [3, 4], and because the aldosterone level was probably
very low to begin with, a diminished ability to tolerate a
potassium load is not unexpected in today's patient, Second,
the potassium was administered without food to a woman
whose basal and stimulated insulin levels were no doubt sup-
pressed by anorexia nervosa and hypokalemia; her relative
insulin deficiency also must have compromised cellular potas-
sium uptake. Third, fasting or decreased food intake decreases
sympathetic activity [74], and the decreased beta-adrenergic
activity associated with the starved state would be expected to
further impair cellular potassium uptake. Augmented alpha-
adrenergic activity might have served as a protective mecha-
nism to maintain the plasma potassium level while she was
depleted, but it is possible that the stimulated alpha-adrenergic
activity can persist long enough to impair potassium tolerance
when potassium is administered so rapidly. In short, transient
hyperkalemia from potassium replacement in patients with
impaired potassium tolerance can be avoided if: (1) the quantity
of potassium replaced is modified for patient size; (2) the doses
of potassium given are sharply curtailed as the serum level
rises; and (3) monitoring of the serum level is continued with
equal diligence as normokalemia is approached.
Extrarenal causes of hyperkalemia
Although decreased urinary potassium excretion due to renal
failure or mineralocorticoid insufficiency accounts for the ma-
jority of cases of hyperkalemia in clinical practice, extrarenal
factors that can cause or contribute to hyperkalemia by redis-
tribution are being recognized more frequently (Table 3). Be-
cause multiple mechanisms exist for promoting potassium tol-
erance, often the coexistence of several partial defects results in
serious elevations of the plasma potassium. Diabetic patients
are particularly prone to hyperkalemia because of the possible
concomitance of insulin deficiency, acidosis, and autonomic
insufficiency, together with mild renal failure or hyporeninemic
hypoaldosteronism. In diabetic patients or others prone to
hyperkalemia, each of these predisposing factors must be
carefully assessed before one prescribes nonselective beta-
adrenergic blockers or alpha-adrenergic agonists such as
Gastrointestinal losses
Vomiting (mainly renal K loss)
Diarrhea
Villous adenoma
Laxative abuse
Skin losses
Sweat
Burns
Redistribution of potassium from extracellular to intracellular fluid
Alkalosis
Insulin
Glucose infusion (endogenous insulin)
Bcta-adrenergic agonists
Recovery from hypothermia or hypoxia
Recovery from exercise
Extensive physical conditioning
Barium poisoning
Familial hypokalemic periodic paralysis
Vitamin B12 therapy of pernicious anemia
phenylephrine. The same considerations pertain to persons who
engage in vigorous exercise; in this circumstance, exaggeration
of the usually mild hyperkalemia of exercise can cause sudden
death due to cardiac toxicity [1]. Tissue necrosis such as
rhabdomyolysis, chemotherapy cell lysis [82], digitalis poison-
ing [83], succinylcholine [84] or arginine [851 administration,
and the rare hyperkalemic periodic paralysis [86] all have been
associated with hyperkalemia, which occurs when potassium
shifts from the intracellular to the extracellular fluid compart-
ment. The same phenomenon can occur in the test tube [87];
pseudohyperkalemia, easily diagnosed when caused by hemo-
lysis, can be detected when caused by thrombocytosis or
leukemia; one merely draws a blood sample into a heparin-
treated tube to promptly measure a normal potassium level in
the plasma, rather than the elevated serum level that occurs due
to potassium release during clotting.
Extrarenal causes of hypokalemiu
Extrarenal potassium losses via the gastrointestinal tract, or
less commonly, the skin, are easily recognized causes of
potassium wasting (Table 4), but redistribution of potassium
from the extracellular fluid to the intracellular fluid is now
known to be a more common cause of hypokalemia. Alkalosis
causes renal potassium losses and a shift of potassium into
cells; insulin, as well as glucose infusions (which stimulate
endogenous insulin production), are frequent causes of hypo-
kalemia. Beta-adrenergic agonists, such as epinephrine [53—57,
61], isoproterenol [53—55, 62], or terbutaline [62] can cause
hypokalemia, and salbutamol can cause profound hypokalemia,
which can be reversed by propranolol administration [88, 89].
Similarly, endogenous beta-adrenergic activity may decrease
the plasma potassium in patients with acute myocardial
infarction [651; some researchers have proposed that this reduc-
tion in serum potassium increases the risk of rhythm distur-
bances in such patients. Recovery from hypothermia, hypoxia,
or exercise can result in enough "overshoot" of cellular potas-
sium uptake to cause transient hypokalemia [1]. Likewise,
extensive physical training can produce mild hypokalcmia as a
form of potassium adaptation. This adaptation is manifested by
enhanced muscle cell potassium uptake and by hyperpolariza-
Table 4. Extrarenal causes of hypokalemia
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tion without potassium deficiency [11. The rare occurrence of
barium poisoning with acid-soluble barium salts always causes
hypokalemia because of the inhibition of cellular potassium
efflux by barium, without suppression of potassium influx [90].
The severe hypokalemia produces muscle paralysis that is
correctable by potassium administration, which restores the
ratio of intracellular to extracellular potassium [901. In familial
hypokalemic periodic paralysis, muscle cell uptake of potas-
sium is increased, causing hypokalemia during a paralytic
attack [91], but treatment with potassium replacement is not
often effective. Mild hypokalemia due to a rapid proliferation of
bone marrow cells with cellular potassium uptake also has been
described during vitamin B12 therapy of pernicious anemia [92].
In conclusion, an appreciation of the physiology of potassium
homeostasis must include the factors that control extrarenal
potassium distribution in addition to those affecting renal po-
tassium excretion. Spontaneous or iatrogenic disorders of the
mechanisms regulating potassium distribution often are unsus-
pected causes of hypokalemia and hyperkalemia; attention to
these disorders helps ensure appropriate management of de-
rangements of potassium metabolism.
Questions and answers
DR. VINCENT J. CANZANELLO (Division of Nephrology,
NEMCI-I): Do you think that a direct action on the sodium-
potassium ATPase pump is the mechanism of insulin- and/or
catecholamine-stimulated potassium uptake by cells? Is there
any evidence that these agents can alter membrane permeability
to potassium independent of an effect on the pump?
DR. BROWN: Both the insulin effect and the beta catechola-
mine effect appear to be mediated by activation of the sodium
pump. Insulin seems to have a direct stimulatory effect on
sodium-potassium ATPase with rapid hyperpolarization of the
cell [30]; this increased electronegativity is then sufficient to
promote cellular uptake of potassium cations. The beta2-adre-
nergic effect on the sodium pump is indirect, apparently medi-
ated by stimulation of adenylate cyclase and generation of
cyclic AMP, which activate sodium-potassium ATPase [70—731.
The effect of epinephrine on cellular potassium influx is en-
hanced by theophylline [70, 71] and blocked by ouabain [70].
Ouabain's ability to block sodium-potassium ATPase and
simultaneously completely block epinephrine-induced potas-
sium influx suggests that a sodium pump effect can account for
this catecholamine action without changing membrane perme-
ability to potassium. However, considerable evidence indicates
that insulin alters cell membrane permeability, causing an
increase in the relative permeability of potassium to sodium [931
and an increase in sodium-hydrogen exchange [31], which
together favor cellular influx of potassium.
DR. RONALD PERRONE (Division of Nephroiogy, NEMCJ-I):
Dr. Brown, what do you advise your healthy patients who are
taking beta blockers regarding exercise and hyperkalemia?
DR. BROWN: We know that beta blockers will augment and
prolong the hyperkalemia of exercise. However, there are many
healthy people taking beta blockers for hypertension who are
exercising without adverse consequences yet identified. I have
no advice for these patients unless they have a concomitant
condition that impairs potassium tolerance. For patients prone
to hyperkalemia, such as those with severe renal failure,
hypoaldosteronism, or insulin-dependent diabetes mellitus, I
would not favor using a beta blocker if the patient engages in the
kind of vigorous exertion that could cause potentially serious
potassium elevations, at least until we obtain more data under
monitored conditions. I also would avoid causing combined
defects in the potassium homeostatic mechanisms by the use of
drug combinations that promote excessive hyperkalemia, such
as angiotensin converting enzyme inhibitors, potassium-sparing
diuretics, and beta blockers given together.
DR. KASSIRER: You mentioned one study of the influence of
catecholamines on serum potassium. Have systematic studies
of the effect of catecholamines at various levels of potassium
deficiency been performed? Is there a titration curve of cate-
cholamine effect, from the severely potassium-depleted animal
on the one hand to a potassium-loaded animal on the other?
DR. BROWN: Not that I know of; such an experiment might
examine the effects of alpha or beta blockers in animals with
hypokalemia and hyperkalemia as a means of assessing the
ambient tone of the alpha- or beta-adrenergic system. One
might predict that with potassium depletion, alpha-adrenergic
activity would be increased, thus maintaining the serum potas-
sium level, and beta-adrenergic activity might be reduced. in
this case, alpha blockade would decrease the serum potassium
level, and beta blockade might be ineffective at increasing it. In
potassium-loaded animals, the opposite would he expected;
beta blockade would show a greater effect by blocking the
heightened beta-adrenergic activity needed to prevent hyperka-
lemia. In our experiments in normal human subjects, neither
alpha blockade with phentolamine nor beta blockade with
propranolol had any acute effect on the serum potassium in the
absence of a concomitant potassium load, although other
groups have demonstrated a slight elevation of the serum
potassium level due to redistribution out of cells in patients
given propranolol chronically [60, 94].
DR. KASSIRER: I was trying to understand whether the
influence of catecholamines, or perhaps epinephrine in partic-
ular, is different at different levels of potassium balance.
DR. BROWN: That is also untested to my knowledge. I
presume that changes in receptor quantity or affinity, changes in
sodium pump activity, or alterations in membrane permeability
can have an influence on the effect of epinephrine in states of
potassium depletion as compared with potassium excess. How-
ever, this question remains to be studied.
DR. KASSIRER: I acknowledge that stress-related epinephrine
release can lower the serum potassium concentration in patients
with acute myocardial infarctions, particularly in patients pre-
viously treated with diuretics, and I appreciate the concern that
hypokalemia could increase the risk of life-threatening ventric-
ular arrhythmias in these patients. But Drs. Harrington, isner,
and I were unable to find convincing evidence of a causal
connection between diuretic use and serious arrhythmias fol-
lowing myocardial infarctions [95, 96]. Do you know of any
such data?
DR. BROWN: Recently, Nordrehaug et al have reported
several studies that address this crucial question. They found
that following acute myocardial infarction, the serum potassium
level correlated negatively with ventricular tachycardia and
frequent unifocal premature ventricular contractions [97]. Fur-
thermore, hypokalemia was more frequent when diuretics were
used, and hypokalemia was associated with an increased fre-
quency of ventricular fibrillation, although short-term mortality
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following acute myocardial infarction was unchanged [98].
Because the serum potassium correlated negatively with the
plasma epinephrine and rose more in the patients with myocar-
dial infarctions who were treated with timolol [99], one could
argue that beta blockade is protective in such patients, at least
partly because of its effect on potassium.
DR. MAmAs: You mentioned that increments in plasma
potassium of at least 1 mEq/liter are required to induce signif-
icant increases in plasma insulin. Has this issue been examined
in the portal circulation, as opposed to merely in peripheral
blood? Smaller changes in plasma potassium also might induce
insulin secretion that is masked by the known large capacity of
the liver for insulin extraction.
DR. BROWN: I know of no studies that examined portal vein
insulin levels in animals given a small potassium load. This
question is quite pertinent, because it has been shown that
insulin initially stimulates the liver to take up potassium.
Possibly this action would suffice for small potassium loads.
The sustained insulin effect appears to be mediated by skeletal
muscle, which may be the reservoir for larger potassium loads
that increase peripheral insulin levels.
DR. NICOLAO5 E. MAmAs: I should like to comment that
recent data by Adrogué and colleagues have suggested a role for
the endocrine pancreas to account for the disparity between
organic acid acidosis and mineral acid acidosis regarding
changes in plasma potassium concentration [1001. Whereas
experimental ketoacidosis in the dog (characterized by normo-
kalemia or hypokalemia) was associated with hyperinsulinemia,
HC1-induced acidosis (characterized by hyperkalemia) was
accompanied by elevated glucagon levels.
DR. BROWN: Thank you, Dr. Madias. That is an interesting
observation.
DR. ANDREW S. LEvEY (Division of Nephrology, AT EMCI-I):
For our patients on dialysis, what are the relative influences of
diet and alterations in extrarenal potassium metabolism on the
serum potassium levels?
DR. BROWN: Extrarenal potassium tolerance is an important
protective mechanism in patients on dialysis. To achieve a
balance of total body potassium, the dialysis and gastrointesti-
nal potassium excretion must equal dietary potassium intake in
anuric patients. Most dialysis patients therefore require limita-
tion of dietary intake, even though it is well recognized that
colonic secretion of potassium can augment fecal potassium
excretion [1011. Controversy exists, however, about the role of
cellular potassium uptake in maintaining potassium tolerance
between dialysis treatments in uremic patients. Studies with
conflicting results showing impaired, normal, or increased
extrarenal disposal of potassium loads were recently reviewed
by DeFronzo and Bia [18]. It appears that resistance to cate-
eholamine-stimulated potassium uptake and diminished sodi-
um-potassium ATPase activity shown in red blood cells may
impair potassium tolerance, whereas insulin-mediated potas-
sium uptake is normal in uremic patients. The role of aldoster-
one in such patients remains to be clarified; data from our
laboratory appear to document an acute, but not chronic, ability
of aldosterone to improve disposal of a potassium load. Varia-
tion of extrarenal potassium tolerance from patient to patient
might explain disparities in potassium levels that we often
cannot ascribe to dietary indiscretion. More study is needed,
but fortunately the cardiac resistance to hyperkalemic ar-
rhythmias, which has been described in potassium-adapted
animals, seems to protect some of our patients who manifest
recurrent, severe hyperkalemia.
DR. MAmAs: You mentioned the importance of adrenergic
activity in extrarenal potassium homeostasis. Are there any
data suggesting that patients with autonomic insufficiency have
disordered potassium tolerance?
DR. BROWN: Not that I know of.
DR. PERRONE: Some old data from Hayes, McLeod, and
Robinson regarding colonic potassium excretion in chronic
renal failure showed fairly substantial colonic potassium excre-
tion in these patients [101]. The authors were unable to show
consistent effects of spironolactone and thus could not draw
any conclusions regarding the effect of aldosterone. Is there any
additional information in this area?
DR. BROWN: Hayes et al documented elevated fecal potas-
sium excretion in uremic patients, which accounted for a
considerable proportion of the dietary intake [101]. The failure
of spironolactone to affect fecal potassium excretion that this
group described has been confirmed by data from our labora-
tory showing that spironolactone or deoxycorticosterone ace-
tate failed to affect the high potassium-to-sodium concentra-
tions in the feces of anephric dialysis patients. It seems likely
that colonic adaptation augments potassium secretion in these
patients and that this adaptation is independent of mineralocor-
ticoid activity. This effect is similar to that in potassium-loaded
rats that were adrenalectomized and that received only physi-
ologic amounts of glucocorticoid [102]. However, total colonic
potassium excretion depends on the wet weight of the feces,
and because most of our dialysis patients were mildly consti-
pated, possibly because of phosphate binders, the fecal potas-
sium excretion was quite low, amounting to only about 10% of
the potassium intake.
DR. PERRONE: Using a nephrectomized dog model, Sterns
showed marked fluctuations in the plasma potassium associated
with parallel changes in the serum insulin and catecholamines
[58, 103]. Since the use of somatostatin blocked the changes in
insulin but not the change in potassium, it seems that catechol-
amines must account for this effect. Are you aware of any data
in humans showing similar large (Ito 2 mEq), minute-to-minute
fluctuations in the plasma potassium level?
DR. BROWN: No, I'm not. In normal humans at rest we noted
little variation in the serum potassium levels measured every 30
minutes; we have not looked for this phenomenon in our
anephric patients in whom catecholamine levels would be high,
as in most dialysis patients. Patients with acute, rather than
chronic, renal failure might manifest variations in potassium
levels analogous to those in nephrectomized dogs.
Da. MAmAs: Recent data have suggested that hyperkalemia-
induced aldosterone secretion is dependent on angiotensin II
[104]. Have studies examined the influence of captopril on
potassium tolerance?
DR. BROWN: Captopril, and presumably other angiotensin
converting enzyme inhibitors, can cause hyperkalemia by re-
ducing aldosterone secretion in patients with renal insufficiency
[105] or severe congestive heart failure [106]. As you have
indicated, the mechanism appears to be a decrease of aldoster-
one secretion due to impaired sensitivity of the adrenal zona
glomerulosa to potassium in vitro. This mechanism was dem-
onstrated when angiotensin II was reduced in rats by pretreat-
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ment with captopril I07j. No study has examined whether the
elevation of the serum potassium with captopril is due to
decreased renal excretion or to decreased extrarenal tolerance
to potassium that has been caused by the hypoaldosteronism.
Reprint requests to Dr. R. Brolvn, Renal Division, Beth Israel
Hospital, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
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